GILD

Gilead Sciences, Inc.

73.58 USD
+0.03 (+0.04%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Gilead Sciences, Inc. stock is down -7.47% since 30 days ago. The dividend yield is 4.02% and its next earnings date is Apr 25, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 41.94% of the previous 30 February’s closed higher than January. In the last 10 Unusual Options Trades, there were 6 CALLs, 4 PUTs. 25% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
22 Feb 16:01 16 Jan, 2026 65.00 CALL 22 89
23 Feb 14:51 21 Jun, 2024 72.50 CALL 96 563
23 Feb 14:54 17 Jan, 2025 80.00 CALL 145 2095
23 Feb 14:58 15 Mar, 2024 75.00 CALL 368 6546
23 Feb 15:35 28 Mar, 2024 70.00 PUT 849 36
23 Feb 18:51 20 Jun, 2025 65.00 PUT 299 378
23 Feb 18:55 20 Jun, 2025 65.00 PUT 300 378
23 Feb 20:04 16 Aug, 2024 75.00 CALL 68 452
23 Feb 20:14 16 Jan, 2026 55.00 PUT 180 294
23 Feb 20:52 20 Jun, 2025 70.00 CALL 36 36

About Gilead Sciences, Inc.

Gilead Sciences discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, and Atripla products for the treatment of HIV/AIDS.

  • Mizuho
    Thu Feb 22, 11:25
    buy
    confirm
  • Truist Securities
    Thu Feb 22, 07:27
    hold
    downgrade
  • RBC Capital
    Wed Feb 14, 10:17
    hold
    confirm
  • Barclays
    Mon Feb 12, 12:08
    hold
    confirm
  • Oppenheimer
    Mon Feb 12, 08:37
    buy
    confirm
  • Cantor Fitzgerald
    Wed Feb 7, 13:42
    hold
    confirm
  • RBC Capital
    Wed Feb 7, 12:07
    hold
    confirm
  • Wells Fargo
    Wed Feb 7, 10:23
    hold
    confirm